Life sciences-focused Rosetta Capital has led a CHF 60m ($66m) series-B funding round for Swiss biotech Novimmune.
Tresmares Capital will also manage a €900m private debt fund to finance the expansion of Spanish SMEs
PAI's Richard Howell, Livingbridge's Susie Stanford and more discuss PE developments throughout 2019 and expectations for the year ahead
Deal includes three manufacturing facilities located in Spain, which employ around 140 staff
GP acquired the care home group from Swiss Prime Site and will be the company's sole shareholder